Belantamab mafodotin: from clinical trials data to real-life experiences
S Morè, M Offidani, L Corvatta, MT Petrucci, F Fazio - Cancers, 2023 - mdpi.com
Simple Summary This paper deals with Belantamab mafodotin, a novel anti-BCMA antibody-
drug conjugate licensed by regulatory agencies for the treatment of anti-CD38-refractory …
drug conjugate licensed by regulatory agencies for the treatment of anti-CD38-refractory …
Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases
W Kantasiripitak, Z Wang, I Spriet… - Expert Review of …, 2021 - Taylor & Francis
Introduction Less than 50% of patients with inflammatory bowel diseases (IBD) receiving
monoclonal antibody (mAb) therapy achieve endoscopic remission. Poor outcomes may …
monoclonal antibody (mAb) therapy achieve endoscopic remission. Poor outcomes may …
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
R Iula, D De Novellis, F Trastulli, R Della Pepa… - Frontiers in …, 2022 - frontiersin.org
Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed
multiple myeloma (MM) patients; however, available real-life experiences on efficacy and …
multiple myeloma (MM) patients; however, available real-life experiences on efficacy and …
Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA/CD16A bispecific tetravalent antibody for the treatment …
H Cai, S Kakiuchi-Kiyota, R Hendricks, S Zhong, L Liu… - The AAPS Journal, 2022 - Springer
Abstract RO7297089, an anti-B-cell maturation antigen (BCMA)/CD16A bispecific tetravalent
antibody, is being developed as a multiple myeloma (MM) therapeutic. This study …
antibody, is being developed as a multiple myeloma (MM) therapeutic. This study …
Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
G Ferron‐Brady, C Rathi, J Collins… - Clinical …, 2021 - Wiley Online Library
Belantamab mafodotin is an antibody–drug conjugate comprising a humanized anti‐B‐cell
maturation antigen (BCMA) monoclonal antibody conjugated to monomethyl auristatin F …
maturation antigen (BCMA) monoclonal antibody conjugated to monomethyl auristatin F …
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
A Suvannasankha, N Bahlis, S Trudel, K Weisel… - Cancer, 2024 - Wiley Online Library
Background Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in
relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that …
relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that …
Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature
JR Proctor, H Wong - Clinical and Translational Science, 2024 - Wiley Online Library
Exposure–response (ER) analysis is used to optimize dose and dose regimens during
clinical development. Characterization of relationships between drug exposure and efficacy …
clinical development. Characterization of relationships between drug exposure and efficacy …
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and‐2 studies
RC Jewell, RJ Mills, C Farrell… - British Journal of Clinical …, 2024 - Wiley Online Library
Aims To evaluate relationships between plasma concentrations of belantamab mafodotin,
total monoclonal antibody, and its payload and changes in electrocardiogram (ECG) …
total monoclonal antibody, and its payload and changes in electrocardiogram (ECG) …
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
Belantamab mafodotin, a monomethyl auristatin F (MMAF)–containing monoclonal antibody‐
drug conjugate (ADC), demonstrated deep and durable responses in the DRiving …
drug conjugate (ADC), demonstrated deep and durable responses in the DRiving …
Teclistamab: Mechanism of action, clinical, and translational science
Y Guo, NA Quijano Cardé, L Kang… - Clinical and …, 2024 - Wiley Online Library
Multiple myeloma (MM) remains incurable despite improvements in treatment options. B‐cell
maturation antigen (BCMA) is predominantly expressed in B‐lineage cells and represents a …
maturation antigen (BCMA) is predominantly expressed in B‐lineage cells and represents a …